This study is testing if a medication called Protonix (pantoprazole) can help prevent acute kidney injury (AKI) after heart surgery. AKI is a common problem after heart surgery and can lead to worse health outcomes. Researchers believe Protonix might protect your kidneys by activating certain pathways. You could be eligible if you are an adult (18-90 years old) having planned heart surgery with a moderate to high risk of AKI. You cannot join if you have severe kidney problems, are on dialysis, need emergency surgery, or are pregnant. The study will compare Protonix to another medication called Pepcid (famotidine). Success will be measured by how many people develop AKI within 7 days of surgery or before leaving the hospital, and other kidney-related events up to 30 days after surgery. The current status of this study is unclear.

Study design

This is a randomized, controlled, single-blinded study involving 400 participants. Participants will receive either Protonix or Pepcid for 3 days.

What's involved

You would receive either Protonix or Pepcid for 3 days, starting before your heart surgery and continuing every 12 hours. Your kidney health will be monitored for up to 7 days or until hospital discharge, and for major kidney events up to 30 days after surgery.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for the incidence of Acute Kidney Injury (AKI) from enrollment to 7 days or until hospital discharge, if earlier. Major adverse kidney events (MAKE) will be monitored at day 30 postoperatively.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.